Ocular Therapeutix, Inc. (OCUL) News
Filter OCUL News Items
OCUL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCUL News Highlights
- For OCUL, its 30 day story count is now at 5.
- Over the past 6 days, the trend for OCUL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- EYE are the most mentioned tickers in articles about OCUL.
Latest OCUL News From Around the Web
Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.
These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS ForecastsMarket forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts... |
Ocular Therapeutix™ to Participate at Three Upcoming Investor ConferencesBEDFORD, Mass., November 08, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: |
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue EstimatesOcular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business UpdateBEDFORD, Mass, November 07, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended September 30, 2022, and provided updates on its ophthalmology pipeline. |
Ocular Therapeutix™ To Report Third Quarter 2022 Financial ResultsBEDFORD, Mass., October 24, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2022 financial results after the close on Monday, November 7, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference |
Investors in Ocular Therapeutix (NASDAQ:OCUL) have unfortunately lost 63% over the last yearInvesting in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Ocular... |
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear MarketFollowing insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. |
Berenberg Bank Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)In a report released today, Caroline Palomeque from Berenberg Bank maintained a Buy rating on Ocular Therapeutix (OCUL - Research Report), with a price target of $15.00. The company's shares closed last Friday at $4.15.Palomeque covers the Healthcare sector, focusing on stocks such as RegenXBio, Anavex Life Sciences, and Ocular Therapeutix. According to TipRanks, Palomeque has an average return of -15.5% and a 29.81% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $15.00 average price target, implying a 261.45% upside from current levels. |
H.C. Wainwright Keeps Their Buy Rating on Ocular Therapeutix (OCUL)H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (OCUL - Research Report) today and set a price target of $10.00. The company's shares closed last Friday at $4.15.According to TipRanks, Chen is an analyst with an average return of -22.4% and a 26.30% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Belite Bio, Inc. ADR, and Applied DNA Sciences.Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $15.00, implying a 261.45% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $15. |